MREO (Mereo BioPharma Group) ROE % Adjusted to Book Value: -46.26% (As of Mar. 2026)


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group ROE % Adjusted to Book Value?

Mereo BioPharma Group MREO +3.62% 19 ROE % Adjusted to Book Value is -46.26% as of Mar. 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Mereo BioPharma Group's ROE % for the quarter that ended in Mar. 2026 was -71.70%. Mereo BioPharma Group's PB Ratio for the quarter that ended in Mar. 2026 was 1.55. Mereo BioPharma Group's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -46.26%.

Mereo BioPharma Group ROE % Adjusted to Book Value Related Terms

Mereo BioPharma Group ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Mereo BioPharma Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group ROE % Adjusted to Book Value Chart

Mereo BioPharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.24 -27.26 -9.03 -8.71 -50.75

Mereo BioPharma Group Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.31 -12.87 -7.93 -41.48 -46.26

MREO vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's ROE % Adjusted to Book Value falls into.


MREO
19GF Score
Mereo BioPharma Group PLC MREO
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mereo BioPharma Group ROE % Adjusted to Book Value Calculation

Mereo BioPharma Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-82.21% / 1.62
=-50.75%

Mereo BioPharma Group's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-71.70% / 1.55
=-46.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -46.26% mean?
Mereo BioPharma Group (MREO) has a ROE % Adjusted to Book Value of -46.26% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mereo BioPharma Group and its competitors.
Is Mereo BioPharma Group's ROE % Adjusted to Book Value too high?
Mereo BioPharma Group's current ROE % Adjusted to Book Value is -46.26%. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's ROE % Adjusted to Book Value compare to VRTX and REGN?
Mereo BioPharma Group's ROE % Adjusted to Book Value of -46.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mereo BioPharma Group and its competitors. Mereo BioPharma Group's current ROE % Adjusted to Book Value is -46.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current ROE % Adjusted to Book Value of -46.26%. The current ROE % Adjusted to Book Value is -46.26%. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current ROE % Adjusted to Book Value is -46.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price